亚太地区胃轻瘫市场预测至 2028 年 - COVID-19 影响和区域分析(按类型(特发性、糖尿病、手术后等)、药物类别(促动力剂、肉毒杆菌毒素注射剂和止吐剂)和分销渠道(零售药房、医院药房等)

Historic Data: 2018-2019   |   Base Year: 2020   |   Forecast Period: 2021-2027


No. of Pages: 109    |    Report Code: TIPRE00024820    |    Category: Life Sciences

Asia-Pacific Gastroparesis Market

市场介绍

亚太地区包括中国、日本、印度、澳大利亚、韩国和亚太地区其他国家/地区。由于该地区糖尿病患者人数众多、研究数量不断增加、政府支持不断增加以及初创公司、制药和生物技术公司数量不断增加,该地区成为 2019 年全球胃轻瘫市场增长最快的地区。胃轻瘫(Gp)是一种慢性疾病,临床症状包括早饱、恶心、腹胀、呕吐和腹痛。亚太地区胃轻瘫市场的其余部分归因于胃轻瘫市场网络研讨会、研究和会议的不断增加。例如,2019 年 4 月,菲律宾医学会举办了关于“糖尿病性胃轻瘫和糖尿病中的胃肠道问题”的网络研讨会。此外,2020年11月,《Journal of Neurogastroenterology and Motility》发表了亚洲神经胃肠病学和运动协会关于亚洲胃轻瘫的知识、态度和实践调查的报告,标题为:亚洲胃轻瘫。新加坡、菲律宾、韩国、台湾、泰国、越南)参与了此次调查。因此,这些因素可能会在预测年内推动胃轻瘫市场的发展。

亚太地区国家正面临着由于 COVID-19 发病率增加而带来的挑战。疫情严重影响医药行业,导致供应链中断;此外,由于医疗基础设施短缺,胃轻瘫药物(如促动力剂、肉毒毒素注射剂、止吐剂等)需求减少,低收入国家面临更多挑战。此外,政府倾向于继续允许商业运营和经济活动。因此,消费保健品或止吐药、促动力药等非处方药的供应受到的影响较小。例如,印度是最大的药品制造中心之一。该国占全球仿制药和品牌药供应的大部分份额。制造商正在满负荷运转。因此,预计相关市场的产品需求和供应将保持不变。疫情对医药行业造成严重影响,导致供应链中断;此外,低收入国家由于医疗基础设施短缺而面临更多挑战。韩国、马来西亚、新加坡、菲律宾和印度已采取限制措施,以防止疾病传播。    

 

           

市场概况和动态

亚太地区胃轻瘫市场预计将从 1,164.94 美元增长 2020年为100万美元,到2027年为16.2377亿美元;预计2020年至2027年复合年增长率为4.9%。糖尿病是一种危及生命的慢性疾病,主要是由于人体无法产生胰岛素或有效利用胰岛素而引起的。糖尿病是21世纪的突发卫生事件之一。根据国际糖尿病联盟(IDF)2019年发布的报告,全球每11人中就有1人患有糖尿病。此外,美国国立卫生研究院(NIH)也报告称,1型糖尿病的发病率正在迅速增加,并且该疾病正在影响相当数量的儿童和青少年。糖尿病是已知的胃轻瘫的主要原因之一。这种疾病的特点是神经受损,尤其是迷走神经和胃壁细胞受损。迷走神经受损会影响胃和小肠的肌肉运动。       

主要细分市场

亚太地区胃轻瘫市场细分为类型、药品类别、分销渠道和国家/地区的基础。亚太地区胃轻瘫市场按类型分为特发性胃轻瘫、糖尿病性胃轻瘫、手术后胃轻瘫等。特发性细分市场在 2019 年占据最大市场份额。亚太地区胃轻瘫市场按药物类别分为促动力剂、肉毒毒素注射剂和止吐剂。促动力剂细分市场在 2019 年占据最大市场份额。根据分销渠道,亚太地区胃轻瘫市场分为零售药房、医院药房等。 2019 年,医院药房市场占据最大份额。按国家/地区划分,亚太地区胃轻瘫市场分为澳大利亚、中国、印度、日本、韩国和亚太地区其他地区。 2019 年日本占据最大市场份额。

主要来源和上市公司

准备本报告时参考的一些主要一手和二手来源亚太地区的胃轻瘫市场包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有Allergan Plc; Bausch Health Companies Inc.(Salix Pharmaceuticals, Ltd.); Ipca 实验室有限公司;强生服务公司;辉瑞公司;和梯瓦制药工业有限公司。         

购买报告的理由

  • 了解亚太地区胃轻瘫市场格局,并确定最有可能保证强劲回报的细分市场。
  • 通过理解来保持竞争优势亚太地区胃轻瘫市场不断变化的竞争格局。
  • 通过识别最有可能销售前景的细分市场,有效规划亚太地区胃轻瘫市场的并购和合作交易。
  • 帮助通过对亚太地区胃轻瘫市场各个细分市场的市场表现进行敏锐和全面的分析,做出明智的业务决策。
  • 获取 2021-2028 年亚太地区各个细分市场的市场收入预测

亚太地区

胃轻瘫市场

细分

亚太地区胃轻瘫市场 -

按类型

  • 特发性
  • 糖尿病
  • 术后
  • 其他

亚太地区胃轻瘫市场 - 作者:

药品类别

  • 促动力剂
  • 肉毒杆菌毒素注射剂
  • 止吐剂

亚太地区胃轻瘫市场 –按分销渠道划分

  • 医院药房
  • 零售药房
  • 其他

亚太地区胃轻瘫市场 - 按国家/地区

  • 澳大利亚   
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太地区其他地区

亚太地区胃轻瘫市场 - 公司简介< /strong>

  • Allergan Plc
  • Bausch Health Companies Inc.(Salix Pharmaceuticals, Ltd.)
  • Ipca Laboratories Ltd.
  • < li>强生服务公司
  • 辉瑞公司
  • 梯瓦制药工业有限公司
 

Asia-Pacific Gastroparesis Strategic Insights

Strategic insights for Asia-Pacific Gastroparesis involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/asia-pacific-gastroparesis-market-strategic-framework.webp
Get more information on this report

Asia-Pacific Gastroparesis Report Scope

Report Attribute Details
Market size in 2020 US$ 1,164.94 Million
Market Size by 2027 US$ 1,623.77 Million
Global CAGR (2020 - 2027) 4.9%
Historical Data 2018-2019
Forecast period 2021-2027
Segments Covered By 类型
  • 特发性
  • 糖尿病性
  • 术后性
By 药物类别
  • 促动力剂
  • 肉毒杆菌毒素注射剂
  • 止吐剂
By 分销渠道
  • 零售药店
  • 医院药店
Regions and Countries Covered 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳大利亚
  • 亚太其他地区
Market leaders and key company profiles
  • Allergan Plc
  • Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  • Ipca Laboratories Ltd.
  • Johnson and Johnson Services, Inc.
  • Pfizer Inc.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Get more information on this report

    Asia-Pacific Gastroparesis Regional Insights

    The regional scope of Asia-Pacific Gastroparesis refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/asia-pacific-gastroparesis-market-geography.webp
    Get more information on this report

    The List of Companies - Asia-Pacific Gastroparesis Market

    1. Allergan Plc
    2. Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
    3. Ipca Laboratories Ltd.
    4. Johnson and Johnson Services, Inc.
    5. Pfizer Inc.
    6. TEVA PHARMACEUTICAL INDUSTRIES LTD
    Frequently Asked Questions
    How big is the Asia-Pacific Gastroparesis Market?

    The Asia-Pacific Gastroparesis Market is valued at US$ 1,164.94 Million in 2020, it is projected to reach US$ 1,623.77 Million by 2027.

    What is the CAGR for Asia-Pacific Gastroparesis Market by (2020 - 2027)?

    As per our report Asia-Pacific Gastroparesis Market, the market size is valued at US$ 1,164.94 Million in 2020, projecting it to reach US$ 1,623.77 Million by 2027. This translates to a CAGR of approximately 4.9% during the forecast period.

    What segments are covered in this report?

    The Asia-Pacific Gastroparesis Market report typically cover these key segments-

  • 类型 (特发性, 糖尿病性, 术后性)
  • 药物类别 (促动力剂, 肉毒杆菌毒素注射剂, 止吐剂)
  • 分销渠道 (零售药店, 医院药店)
  • What is the historic period, base year, and forecast period taken for Asia-Pacific Gastroparesis Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia-Pacific Gastroparesis Market report:

  • Historic Period : 2018-2019
  • Base Year : 2020
  • Forecast Period : 2021-2027
  • Who are the major players in Asia-Pacific Gastroparesis Market?

    The Asia-Pacific Gastroparesis Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Allergan Plc
  • Bausch Health Companies Inc. (Salix Pharmaceuticals, Ltd.)
  • Ipca Laboratories Ltd.
  • Johnson and Johnson Services, Inc.
  • Pfizer Inc.
  • TEVA PHARMACEUTICAL INDUSTRIES LTD
  • Who should buy this report?

    The Asia-Pacific Gastroparesis Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Asia-Pacific Gastroparesis Market value chain can benefit from the information contained in a comprehensive market report.